Residency · Residency · Anesthesiology

Opioid Pharmacology: From Fentanyl to Remifentanil

Opioid Receptor Pharmacology

Receptor Types

Opioid effects are mediated through three main receptor types. The mu (MOP) receptor is the primary receptor mediating analgesia, respiratory depression, euphoria, physical dependence, and decreased GI motility. The kappa (KOP) receptor produces sedation, spinal analgesia, and dysphoria, with less respiratory depression than mu. The delta (DOP) receptor modulates mu activity, contributes to spinal analgesia, and affects mood. All three are G-protein-coupled receptors (Gi/Go) that inhibit adenylyl cyclase, open potassium channels, and close voltage-gated calcium channels.

Signal Transduction

At the presynaptic level, opioid receptor activation decreases calcium influx, which reduces neurotransmitter release (substance P, glutamate). Postsynaptically, increased potassium conductance hyperpolarizes the neuron. Opioids also engage descending inhibition through activation of the periaqueductal gray and rostral ventromedial medulla pathways.

Comparative Pharmacokinetics

Fentanyl

Fentanyl is 100 times as potent as morphine. Its onset is 1-2 minutes IV due to high lipophilicity and rapid CNS penetration, and duration after a single bolus is 30-60 minutes (redistribution-dependent). The context-sensitive half-time increases significantly with prolonged infusion due to accumulation in fat and muscle, reaching approximately 200 minutes after a 4-hour infusion. Metabolism is hepatic via CYP3A4 to norfentanyl (inactive). The volume of distribution is very large (4 L/kg). Clinical uses include intraoperative analgesia, neuraxial administration, and transdermal patches for chronic pain.

Sufentanil

Sufentanil is 500-1000 times as potent as morphine (5-10 times fentanyl) with a slightly faster onset. Its context-sensitive half-time is shorter than fentanyl for infusions up to 8 hours due to higher clearance. Metabolism is hepatic via CYP3A4 with an extensive first-pass effect. Protein binding is 93%, primarily to alpha-1 acid glycoprotein. Clinical uses include cardiac anesthesia (high-dose technique), epidural analgesia, and sublingual formulations (Dsuvia).

Alfentanil

Alfentanil is 10-25 times as potent as morphine (1/5 to 1/10 of fentanyl). Its onset is very rapid (under 1 minute) due to a low pKa of 6.5, which results in a high unionized fraction (90%) at physiologic pH. Duration is short at 10-15 minutes. The context-sensitive half-time is relatively short with a plateau effect that makes it predictable for infusion. The volume of distribution is small (0.4-1.0 L/kg). Metabolism is via CYP3A4 with no active metabolites. It is ideal for blunting the response to short painful stimuli such as laryngoscopy.

Remifentanil

Remifentanil is approximately equipotent to fentanyl with an onset of 1-1.5 minutes. Its unique property is a context-sensitive half-time of 3-4 minutes regardless of infusion duration. This results from metabolism by ester hydrolysis through nonspecific tissue and plasma esterases (not pseudocholinesterase), meaning there is no accumulation and no dependence on hepatic or renal function for clearance. It must be given by infusion because bolus dosing can cause profound bradycardia and chest wall rigidity. A typical infusion range is 0.05-0.5 mcg/kg/min. Clinical uses include TIVA, neurosurgery, cardiac surgery, cases requiring rapid emergence, and scoliosis surgery with neuromonitoring.

Key Pharmacologic Concepts

Context-Sensitive Half-Time

Context-sensitive half-time is the time for plasma concentration to decrease by 50% after stopping an infusion of a given duration. It reflects peripheral compartment loading and redistribution dynamics and is clinically more relevant than elimination half-life for predicting recovery. Remifentanil's flat line at 3-4 minutes regardless of duration contrasts sharply with fentanyl's steep rise to approximately 260 minutes after 4 hours. Sufentanil rises moderately to about 30 minutes after 8 hours, and alfentanil plateaus around 50 minutes after 8 hours.

Effect-Site Equilibration (ke0)

The ke0 describes the rate of drug transfer between plasma and the effect site (brain). A higher ke0 means faster onset. Alfentanil has the highest ke0 among the fentanyl family due to its high unionized fraction, and remifentanil also has a rapid ke0.

Opioid Side Effects

Respiratory Depression

All opioids produce dose-dependent depression of the medullary respiratory center, decreasing sensitivity to CO2 by shifting the CO2 response curve to the right and reducing its slope. Respiratory rate is decreased more than tidal volume. The effect is synergistic with benzodiazepines and other CNS depressants. Remifentanil and sufentanil are particularly potent respiratory depressants at analgesic doses.

Chest Wall Rigidity (Wooden Chest Syndrome)

This emergency presents as sudden-onset truncal and glottic rigidity after rapid IV bolus of potent opioids. The mechanism is central mu-receptor-mediated increase in muscle tone. It is most common with fentanyl, sufentanil, and remifentanil at high doses or with rapid injection. It makes bag-mask ventilation impossible. Treatment requires a neuromuscular blocker (succinylcholine or rocuronium) — naloxone is too slow to be useful.

Cardiovascular Effects

Opioids cause bradycardia through vagal stimulation, especially fentanyl and sufentanil. Mild hypotension can result from histamine release, which is more prominent with morphine and meperidine; synthetic opioids cause minimal histamine release. Overall, synthetic opioids provide hemodynamic stability, which is advantageous in cardiac anesthesia.

Gastrointestinal Effects

Opioids decrease GI motility and increase sphincter tone. They cause nausea and vomiting through chemoreceptor trigger zone stimulation and contribute to postoperative ileus with prolonged use.

Other Effects

Additional effects include miosis (pinpoint pupils — a diagnostic sign), pruritus (especially with neuraxial administration, which is central mu-mediated rather than histamine-mediated), urinary retention, and immune modulation of uncertain clinical significance.

Opioid-Induced Hyperalgesia (OIH)

Definition

OIH is a paradoxical increase in pain sensitivity following opioid exposure. It is distinct from tolerance, which requires escalating doses for the same effect. In OIH, pain spreads beyond the surgical site and allodynia develops to non-noxious stimuli.

Mechanisms

The mechanisms involve NMDA receptor activation and central sensitization, upregulation of pronociceptive pathways (dynorphin, CCK), glial cell activation with neuroinflammation, and spinal cord long-term potentiation.

Clinical Significance

OIH is most commonly associated with remifentanil infusions (acute OIH) and may contribute to increased postoperative opioid requirements. It remains controversial because it is difficult to distinguish from acute tolerance in clinical practice.

Prevention and Treatment

NMDA antagonists — particularly ketamine at 0.1-0.5 mg/kg bolus and 0.1-0.2 mg/kg/hr infusion — are the primary pharmacologic strategy. Multimodal analgesia (NSAIDs, acetaminophen, regional anesthesia), limiting remifentanil infusion rates, and transitional analgesia (administering a longer-acting opioid before stopping remifentanil) all help.

Special Considerations

Remifentanil and Transitional Analgesia

Because remifentanil wears off in 3-4 minutes, patients will have no residual analgesia at emergence. A longer-acting analgesic (morphine, hydromorphone, fentanyl, or multimodal agents) must be administered 20-30 minutes before the end of the case. Failure to provide transitional analgesia is a common cause of severe PACU pain.

Meperidine

Meperidine is falling out of favor. Its active metabolite normeperidine is CNS excitatory (causing seizures) and accumulates in renal impairment. It remains useful for treatment of postoperative shivering through a kappa-receptor mechanism. It carries a risk of serotonin syndrome with MAOIs (an absolute contraindication), and most institutions are restricting or removing it from formulary.

Morphine

Morphine is the prototype opioid and the potency benchmark (1x). Its active metabolite morphine-6-glucuronide (M6G) is potent and renally cleared, accumulating in renal failure. Morphine causes histamine release that can lead to hypotension, bronchospasm, and pruritus. Its onset is slower than synthetic opioids due to lower lipophilicity and a pKa of 7.9.

<image>A comparative pharmacokinetic chart showing the context-sensitive half-times of fentanyl, sufentanil, alfentanil, and remifentanil plotted against infusion duration from 0 to 10 hours. The y-axis shows time in minutes (0-300). Fentanyl rises steeply to over 250 minutes. Sufentanil rises moderately to about 30-40 minutes. Alfentanil plateaus around 50 minutes. Remifentanil remains flat at approximately 3-4 minutes throughout. Key clinical interpretation annotations are included.</image>

<image>A diagram of opioid receptor signaling at a synaptic junction showing: a presynaptic neuron with mu-receptor activation leading to decreased calcium influx and reduced neurotransmitter release, and a postsynaptic neuron showing potassium channel opening and hyperpolarization. Arrows indicate the downstream effects of Gi protein coupling: inhibition of adenylyl cyclase, decreased cAMP, and modulation of ion channels.</image>

<image>A clinical algorithm for managing chest wall rigidity (wooden chest syndrome): recognition triggers (inability to ventilate after rapid opioid bolus, rigid abdomen and thorax), immediate actions (stop opioid, call for help, administer succinylcholine 1-2 mg/kg or rocuronium 1.2 mg/kg IV), followed by intubation and ventilation. Side panel shows prevention strategies: slow injection, dilute opioid, pre-treatment with small NMB dose.</image>

Clinical Pearls

Remifentanil's context-sensitive half-time is uniquely constant at 3-4 minutes, making it ideal for TIVA — but transitional analgesia must always be planned. Chest wall rigidity is a true emergency: do not waste time with naloxone; give a neuromuscular blocker immediately. Alfentanil has the fastest onset of any opioid due to its low pKa (6.5) and high unionized fraction, making it ideal for blunting the response to laryngoscopy. OIH after remifentanil is real but hard to distinguish from tolerance clinically; adding low-dose ketamine is a reasonable prophylactic strategy. Morphine-6-glucuronide accumulation in renal failure can cause delayed respiratory depression hours after the last dose. In cardiac anesthesia, high-dose fentanyl (50-100 mcg/kg) or sufentanil provides hemodynamic stability but delays extubation.

References

• Egan TD. Remifentanil pharmacokinetics and pharmacodynamics: a preliminary appraisal. Clin Pharmacokinet. 1995;29(2):80-94.
• Hughes MA, Glass PS, Jacobs JR. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology. 1992;76(3):334-341.
• Streisand JB, et al. Alfentanil pharmacokinetics. Clin Pharmacol Ther. 1987;42(6):611-616.
• Fletcher D, Martinez V. Opioid-induced hyperalgesia in patients after surgery: a systematic review and meta-analysis. Br J Anaesth. 2014;112(6):991-1004.
• Miller RD, et al. Miller's Anesthesia, 9th edition. Chapter on Opioids.

Read this lecture as Markdown